Amgen (AMGN) Tops Q3 EPS by 41c, FY Guidance Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Amgen Reports Third Quarter 2021 Financial Results
November 2, 2021 4:01 PM EDTTHOUSAND OAKS, Calif., Nov. 2, 2021 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the third quarter of 2021. Key results include:
Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 4% globally, driven by double-digit volume growth across a number of our products, including Prolia® (denosumab), EVENITY® (romosozumab-aqqg), Repatha® (evolocumab) and MVASI® (bevacizumab-awwb).GAAP earnings per share (EPS) decreased 3% to $3.31 driven by a $400 million licensing-related... More